Limited effect of food composition on the pharmacokinetics of nelfinavir administered twice daily.
The objective of the study was to investigate the effect of two different breakfasts on the pharmacokinetics of nelfinavir under steady state conditions.


METHODS
Twenty-four healthy male volunteers were evaluated in a 17 days open labeled one sequence crossover study evaluating the effect of a 'light' breakfast (350 kcal) compared to a standard breakfast (800 kcal) on the pharmacokinetics of nelfinavir at steady state during 1250 mg twice daily (BID) administration.


RESULTS
After administration with a standard breakfast higher concentrations of nelfinavir were observed during the terminal phase than after administration with a 'light' breakfast. The comparison of the log subset 10 transformed parameters C subset 1-hr-postdose, AUC subset 0-12h, C subset max, and C subset 12 hours, showed that the AUC subset 0-12h was decreased by 13% (P = 0.01) after administration with the 'light' breakfast. Nelfinavir 1250 mg BID was well tolerated.


CONCLUSIONS
Although drug intake with a 'light' breakfast' showed a statistically significant decrease for nelfinavir AUC subset 0-12h, this marginal 13% reduction is not considered clinically relevant. No significant effects of the two different breakfasts were found for the remaining three parameters tested C subset 1-hr-postdose, C subset max, and C subset 12 hours.
Kurowski
Michael
M
Therapia GmbH, c/o Auguste Viktoria Krankenhaus, Immunologische Tagesklinik, Rubensstr. 125, 12157 Berlin, Germany. Labor-Kurowski@t-online.de
Kaeser
B
B
Sawyer
A
A
Popescu
M
M
Mroziekiewicz
A
A
Arslan
A
A
Staszewski
S
S
D000328:Adult; D019540:Area Under Curve; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D018565:Food-Drug Interactions; D006801:Humans; D019888:Nelfinavir / Q000008:administration & dosage / Q000493:pharmacokinetics*; D012016:Reference Values; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*
D018894:Reverse Transcriptase Inhibitors; D019888:Nelfinavir